An emerging body of evidence has been involved in plasminogen activator inhibitor-1 (PAI-1) in the development of type 2 diabetes (T2D), though the findings are not always consistent. Our systematic epidemiological studies examining the association of PAI-1 with T2D.
EMBASE, PubMed, Web of Science, and the Cochrane Library were searched to identify studies for inclusion. Fifty-two studies (44 cross-sectional with 47 unique analytical comparisons and 8 candidates) included. In a random-effects pooled analysis of prospective studies, a comparison of the three vs three under basic PAI-1 values generated T2D RR of 1.67 (95% CI 1.28 to 2.18) with moderate heterogeneity (I (2) = 38 %).
In addition, of 47 comparative cross-sectional study, 34 (72%) reported a significant increase in PAI-1 in the case of diabetes compared with controls, 2 (4%) reported significantly increased PAI-1 in the control, and 11 (24%) reported null effect. Results from a pooled analysis of prospective studies did not differ substantially with the study design, the length of follow-up, adjustment for various confounding factors suspected of, or the quality of learning, and robust to sensitivity analysis.
The findings of this systematic review available epidemiological literature supports the relationship between PAI-1 and T2D, established independent risk factor for diabetes. Given the association of moderate size and heterogeneity across studies, prospective studies in the future guaranteed. Women with type 2 diabetes mellitus (T2DM) have a higher risk of fracture despite an increase in bone mineral density (BMD). In the experimental study the potential role of plasminogen activator inhibitor-1 (PAI-1) in bone remodeling advised but studies in humans are lacking.
Plasminogen driving inhibitors -1 concentration and bone mineral density in postmenopausal women with type of two diabetes mellitus.
BACKGROUND Women with type 2 diabetes mellitus (T2DM) have a higher risk of fracture despite an increase in bone mineral density (BMD). In the experimental study the potential role of plasminogen activator inhibitor-1 (PAI-1) in bone remodeling advised but studies in humans are lacking. This is the first study in humans to investigate whether circulating levels of PAI-1 in postmenopausal women with type 2 diabetes associated with BMD and adiposity.
METHOD Anthropometric variables, PAI-1 and insulin, serum lipids and markers of bone turnover were measured in 127 postmenopausal women with type 2 diabetes. A total of 117 female patients were divided according to lumbar spine BMD by dual-energy x-ray absorptiometry measurements in three groups: 47 with osteopenia, 21 with osteoporosis and 49 with normal BMD.4
RESULTS diabetic patients with normal BMD had significantly higher BMI, larger waist circumference and lower bone turnover markers of diabetic patients with osteopenia and osteoporosis. PAI-1 was lower in diabetic patients with osteoporosis and osteopenia compared to diabetics with normal BMD. Multiple regression analysis revealed insulin, triglyceride levels, pyrilinks and beta-blocker therapy to be the strongest predictors of PAI-1 levels. PAI-1 levels correlated with both L-BMD and hip BMD, but after adjustment for age and BMI association was no longer significant.
CONCLUSION Our findings suggest that elevated levels of PAI-1 associated with higher BMD in obese diabetic patients but the possible implications of these findings and the underlying mechanisms remain unclear. Obviously, the metabolic parameters, can affect both BMD and PAI-level, and the association of PAI-1 and metabolism are also reasonable.
Description: SERPINE2 produced in Sf9 Baculovirus cells is a single,glycosylated polypeptide chain containing 386 amino acids (20-397a.a.) andhaving a molecular mass of 42.9kDa (Molecular size on SDS-PAGE will appear atapproximately 40-57kDa).SERPINE2 is expressed with a 8 amino acid His tag atC-Terminus and purified by proprietary chromatographic techniques.
Description: SERPINE1 Human Recombinant fused to N-terminal His-Tag produced in E.Coli is a single, non-glycosylated polypeptide chain containing 400 amino acids (24-402) and having a molecular mass of 45 kDa.;The SERPINE1 is purified by proprietary chromatographic techniques.
Recombinant Human Plasminogen activator inhibitor 1 (SERPINE1), partial
Description: A competitive ELISA for quantitative measurement of Mouse Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A sandwich ELISA for quantitative measurement of Mouse Plasminogen activator inhibitor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A sandwich ELISA for quantitative measurement of Mouse Plasminogen activator inhibitor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A sandwich ELISA for quantitative measurement of Mouse Plasminogen activator inhibitor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Plasminogen Activator Inhibitor 2 (PAI2) in plasma.
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Plasminogen Activator Inhibitor 2 (PAI2) in plasma.
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Plasminogen Activator Inhibitor 2 (PAI2) in plasma.
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Plasminogen Activator Inhibitor 2 (PAI2) in plasma.
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Mouse Plasminogen Activator Inhibitor 2 (PAI2) in samples from plasma with no significant corss-reactivity with analogues from other species.
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse PAI2. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse PAI2. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse PAI2, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse PAI2 in the samples is then determined by comparing the OD of the samples to the standard curve.
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse PAI2. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse PAI2. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse PAI2, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse PAI2 in the samples is then determined by comparing the OD of the samples to the standard curve.
Description: A sandwich ELISA for quantitative measurement of Mouse Plasminogen Activator Inhibitor 1 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A sandwich ELISA for quantitative measurement of Mouse Plasminogen Activator Inhibitor 1 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A sandwich ELISA for quantitative measurement of Mouse Plasminogen Activator Inhibitor 1 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse plasminogen activator inhibitor,PAI in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse plasminogen activator inhibitor,PAI in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse plasminogen activator inhibitor,PAI in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.